Last reviewed · How we verify

Intra-vitreal Anti-VEGF Drug

Retina Vitreous Associates of Florida · Phase 1 active Small molecule

Intra-vitreal Anti-VEGF Drug is a Small molecule drug developed by Retina Vitreous Associates of Florida. It is currently in Phase 1 development. Also known as: Lucentis, Avastin, Eylea.

At a glance

Generic nameIntra-vitreal Anti-VEGF Drug
Also known asLucentis, Avastin, Eylea
SponsorRetina Vitreous Associates of Florida
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intra-vitreal Anti-VEGF Drug

What is Intra-vitreal Anti-VEGF Drug?

Intra-vitreal Anti-VEGF Drug is a Small molecule drug developed by Retina Vitreous Associates of Florida.

Who makes Intra-vitreal Anti-VEGF Drug?

Intra-vitreal Anti-VEGF Drug is developed by Retina Vitreous Associates of Florida (see full Retina Vitreous Associates of Florida pipeline at /company/retina-vitreous-associates-of-florida).

Is Intra-vitreal Anti-VEGF Drug also known as anything else?

Intra-vitreal Anti-VEGF Drug is also known as Lucentis, Avastin, Eylea.

What development phase is Intra-vitreal Anti-VEGF Drug in?

Intra-vitreal Anti-VEGF Drug is in Phase 1.

Related